Call for Abstract

13th International Conference on Biosimilars and Biologics, will be organized around the theme “European Biosimilars: Present Scenario & Future Prospects ”

Biosimilars Congress 2019 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Biosimilars Congress 2019

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Biosimilars are surmounting pharmaceutical business division from most recent three decades and deals appear to extend coherently. Advances in the biotechnology prompt to change and exposure of new natural items (Biosimilars) to treat diverse life-debilitating illnesses. Biosimilars are organic medications that are conveyed after expiry of the patent of affirmed pioneer and include Hatch-Waxman act is the amendment to Federal, Food, Drug and Cosmetics act which established the modern system of approval of generics through Abbreviated New Drug Applications (ANDAs).

 

  • Track 1-1Key Aspects in Technical Development
  • Track 1-2Analysis of the Biosimilar Development Pipeline
  • Track 1-3Legal Issues and Implementation of the BPCI Act

The safeguarding of product trade secret, its formulations and other process parameters by law is usually covered by IPR. It includes those as patents, copyrights, industrial design rights, trademarks etc. IPR is of prime importance in the field of Biologics and Biosimilars. Most scientist and industries tend to retain their monopoly business by exercising the IPR. Currently, the US provides 12 years of exclusivity for new biological products under the Biologics Price Competition and Innovation Act (BPCIA).The provision providing 12 years exclusivity was buried inside the 20,000-page healthcare law. Eight years of exclusivity would keep biologic medicines out of the hands of many who need them. Prices frequently exceed $100,000.

 

  • Track 2-1Pharma patent scenario
  • Track 2-2Criteria for patentability and patent claims
  • Track 2-3Critical research issues
  • Track 2-4Patentable subject matter
  • Track 2-5Recent patent disputes and litigations

biosimilar is an organic item very like an affirmed natural item, known as a kind of perspective item, with no clinically significant contrasts as far as wellbeing and viability. In the U.S., if a natural compound exhibits practically identical information to a U.S. Nourishment and Drug Administration (FDA)- authorized item from expository, preclinical and clinical reviews, it will be acknowledged as a biosimilar after termination of trend-setter licenses through a curtailed course. Tradable natural items are likewise Biosimilars, however should meet extra criteria to coordinate the reference item. Interchangeable can be substituted for the reference item without a medicine from a social insurance supplier.

  • Track 3-1Biosimilar Product Reimbursement and Pricing
  • Track 3-2Biosimilar Regulatory Updates and Legal Implications
  • Track 3-3Biosimilar Market Access and Commercialization

An FDA analysis of drug prices from 1999 to 2004 found that the discount from generic competition was just 6 percent with one generic competitor, but jumps to 48 percent with two generic competitors, 56 percent with three, 61 percent with four and 67 percent with five generic producers in a market. Within two years of the expiration of the patent for the popular drug Zantac in mid-1997, generic versions accounted for 90 percent of the treatment’s total sales, and the price for patients was about 10 percent of its pre-generic price. European patents on biologic treatments began to expire in 2000, and in April 2006, Sandoz and Biopartners received EMEA approval for the first European Biogenerics, two products containing human growth hormone.

  • Track 4-1Biosimilars regulation
  • Track 4-2BLA filing for Biosimilars
  • Track 4-3Regulatory prospects of BRIC countries
  • Track 4-4Aparadigm of traditional generics to Biosimilars
  • Track 4-5Biowaiver approval for Biosimilars
  • Track 4-6Generic Biosimilars
  • Track 4-7Regulatory Prospects in BRIC countries

The legal issues pertaining to the follow-on-Biologics and Biosimilars are one of the most aspects that require an open discussion. Before the actual advent of Biosimilars to the market legal issues have risen in numbers in their developmental stages. Renowned organizations have filed cases against each other two claim their rights and for other legal allegations related to the products. This track is dedicated to discussion of all such cases which has been argued in the court of law. By 2002, the FDA had approved 36 new Biologics, followed by 37 more in 2003, another 40 in 2004 and 39 more in 2005. By 2006, the leading category of biologic treatment, the red blood cell enhancer recombinant erythropoietin (EPO), generated $14 billion in sales revenues, or 40 percent more than the best-selling traditional pharmaceutical, Lipitor. More than 300 therapeutic antibodies currently are in clinical development and trials, compared to just 13 that already are widely available due to legal issues.

  • Track 5-1Implementation of the BPCI Act
  • Track 5-2Patent protection and infringement issues
  • Track 5-3Patent negotiation and litigation phase
  • Track 5-4Market exclusivities

Biosimilars are a relatively new subset of biopharmaceuticals, with the biotechnology industry finally maturing such that off-patent generic-type products increasingly will be entering major markets. So far, more than 20 Biosimilars for a limited number of reference products have been approved in major markets, primarily the European Union. Only two products have been formally approved as Biosimilars in the United States. The parent field of biopharmaceuticals itself continues to exhibit a poor supporting infrastructure of information resources. Those biopharmaceutical and biosimilar information resources that do exist generally are limited in number, diversity, and sophistication.

  • Track 6-1Drug safety of Biosimilars products
  • Track 6-2Regulatory aspects
  • Track 6-3Regulatory affairs and IPR of Biosimilars products

Biosimilar Engineers and their outsourcing accomplices must know about the picked nation's administrative scene, and have broad information of any current Biosimilar endorsement pathway and the most recent administrative organization rules. Furnishing administrative experts with endorsements of investigation (CoA) for a U.S. - advertised comparator could challenge. As opposed to European practice, U.S. makers tend not to make CoAs accessible to parties required in the production network or bolster the improvement of a contender by discharging CoAs for clumps acquired for clinical trials. Giving family proclamations to the reference item more often than not is acknowledged as an option.

  • Track 7-1Product Similarity for Biosimilars & Analytical Challenges
  • Track 7-2Role of Medical Affairs in Biosimilars
  • Track 7-3Regulatory strategy for generics and Biosimilars

The European regulatory authorities led with a specially adapted approval procedure to authorize subsequent versions of previously approved Biologics, termed "similar biological medicinal products", or Biosimilars. This procedure is based on a thorough demonstration of "comparability" of the "similar" product to an existing approved product. In the United States, the Food and Drug Administration (FDA) held that new legislation was required to enable them to approve Biosimilars to those Biologics originally approved through the PHS Act pathway. The FDA gained the authority to approve Biosimilars (including interchangeable that are substitutable with their reference product) as part of the Patient Protection and Affordable Care Act signed by President Obama on March 23, 2010.

  • Track 8-1Biosimilar and Interchangeable Products
  • Track 8-2Biosimilar Development, Review, and Approval
  • Track 8-3Prescribing Biosimilar and Interchangeable Products
  • Track 8-4Biosimilar Product Information
  • Track 8-5Industry Information and Guidance

With Europe that paved way to the uptake of Biosimilars over a decade ago, the consequences of Brexit would be potentially harder on UK. Presently UK is no more bound to follow the guidelines of EMA. Also research grants from Innovative Medicines Initiative and Horizon 2020 would no more be available to UK. All the same, EMA has its headquarters in London, UK. The thus arising complications would definitely have certain consequences on the Biosimilars scenario in UK and EU.

  • Track 9-1Brexit- Pros and Cons to European pharma market
  • Track 9-2Post Brexit changes in Biosimilars regulation in UK
  • Track 9-3Fate of Biosimilars clinical trials in UK
  • Track 9-4Research funding from European organizations to UK based research laboratories

Effective management of a current good manufacturing practice (GMP) facility requires a strict eye on all those factors. This also includes Bioanalytical methods, Formulation, Bioassay for comparability and potency testing, GMP protein analysis, LC/MS analysis for discovery, preclinical, and clinical programs. Analysis of Biosimilars and Biologics forms to be one of the most important aspects towards the Biologics and Biosimilar development process. On average, facilities outsource 32% of their analytical testing/bioassays (up from 28%) meaning that close to one-third of analytical testing is estimated to be outsourced by the industry. The market for Biosimilars follow-on-Biologics is expected to grow at an exponential rate for next decade with the expiry of most patented drugs by 2020.The market in the APAC region for Biosimilars reached $605 million in 2010 and $683 million in 2011. The market is expected to reach $1.1 billion by 2016, a CAGR of 10.3%. The market in the United States for Biosimilars reached $507 million in 2010 and $1.1 billion in 2011. The market is expected to reach $1.3 billion by 2016, a CAGR of 4.1%.

  • Track 10-1Biosimilar bioanalytical methods
  • Track 10-2Biosimilar Formulation
  • Track 10-3Bioassay for comparability and Potency Testing
  • Track 10-4Biosimilar GMP protein analysis
  • Track 10-5Biosimilar lc/ms analysis for discovery, preclinical, and clinical programs
  • Track 10-6Biosimilar Electrophoresis
  • Track 10-7Biosimilar multimodal techniques
  • Track 10-8Biosimilars companies

Biosimilars Market is experiencing a growth at an exponential rate. Presently around 700 Biologics are making progress in the research pipelines of nearly 250 Biopharma companies. Biosimilar insulins have already started revolutionizing the future drug development in the realm of diabetology. Biosimilars of Adalimumab, Etanercept, Rituximab, Peg-Filgrastim, Trastuzumab are expected to hit the market soon. Biosimilar of Humatrope, biosimilar of Eprex, biosimilar of Neupogen, biosimilar of Remicade have already been enjoying a greater market share in Europe than the reference product itself. The proportion of different Biosimilars that reached market are Low Molecular Weight Heparins 44%, Epoetins 19%, HGH 11%, G-CSFs 7%, Interferons 6%, Insulins 5%, Others 8%.

  • Track 11-1Biologics in cancer
  • Track 11-2Biologics for psoriasis
  • Track 11-3Biosimilar monoclonal antibodies
  • Track 11-4Recombinant therapeutic proteins
  • Track 11-5Insulin Biosimilars
  • Track 11-6Biologics in autoimmune disease

The generic version of Biologicals- “Biosimilars” is the new buzz word in the world of pharmaceutical industry. Biosimilars are highly similar to their licensed reference product not withstanding minor differences as excipients in the formulation; also there are no remarkable differences between the Biologicals and the reference product in terms of safety, purity, and potency. However, there are certain challenges in way of its development and receiving a green signal for launching into the market. Newer Biologics also are targeting widespread diseases, with profound implications: a drug that costs $20,000 per year that is useful for 1 person in 100,000 has much less effect on a health plan’s cost structure than a $5,000-per-year drug that is useful for 1 in 100 people.

  • Track 12-1Current concepts of drugs and Biologics
  • Track 12-2Unique considerations for Biologics
  • Track 12-3Early clinical development essentials
  • Track 12-4Late clinical development essentials
  • Track 12-5Drug safety essentials
  • Track 12-6Cancer Therapeutics
  • Track 12-7Comparability for Biologics
  • Track 12-8Quality by Design for Biologics and Biosimilars

Bioequivalence focuses on the equivalence of release of the active pharmaceutical ingredient from the pharmaceutical product and its subsequent absorption into the systemic circulation. This session has utmost importance in context to the fact that only a suitably bioequivalent drug candidate that conforms the results in all respects to the original licensed product can be called as biosimilar drug. Of all attempts towards developing a follow on Biologics or a biosimilar drug the main detection point stands at the Bioequivalence Assessment. Once the bioequivalence has been obtained it can be 70% ascertained the drug qualifies to be a suitable Biologics or Biosimilars.

  • Track 13-1Strategies for the bioequivalence assessment of topical dosage forms
  • Track 13-2Bioequivalence assessment of respiratory dosage forms
  • Track 13-3Bioequivalence approaches for transdermal dosage forms
  • Track 13-4Evaluation of highly variable drugs and drug products

Biological Medicine works with the biology of the body and its natural healing capabilities as well as the spiritual, emotional and physical aspects of disease. Disease means that the body’s regulation is not working properly and needs to be brought back into its natural dynamic state where the immune system is in full regulation.  It therefore looks for root causes for the presenting symptoms of disease the underlying factors causing a person to present with a certain illness.  These root causes may consist of several factors which have built up over time and can include; diet, food allergies, intestinal disturbances, family history, stress, environmental factors, heavy metals, dental problems, hyperacidity, trauma, exposure to bacteria or viruses or electromagnetic disturbances.

  • Track 14-1Advances in Biological products
  • Track 14-2Biological drugs
  • Track 14-3Generic Biological drugs
  • Track 14-4Biotechnology medicinal products for different drugs
  • Track 14-5Future of next generation Biosimilars
  • Track 14-6Biopharmaceuticals development

Biological medicines are much more structurally complex and extremely sensitive to manufacturing conditions and therefore more difficult to characterize and produce than small molecule drugs. Even minor changes in manufacturing may lead to significant variations of the cellular systems used for biological production, as well as to differences in the structure, stability, or other quality aspects of the end product, all of which have the potential to affect tolerability and/or efficacy and increase the risk of immune responses. Owing to these issues, specific regulatory guidance on Biosimilars is continuously evolving, and there is some disagreement on which studies need to be implemented to approve a Biosimilars. According to current literature, the following points on Biosimilars deserve consideration: Biosimilars development is characterized by global harmonization, although several not fully answered questions remain regarding extrapolation of indications, switching or interchange ability, and tolerability; in patients with rheumatic diseases, the tolerability and efficacy of Biosimilars in clinical practice remain to be established; several medical and patient associations have published position papers on Biosimilars requesting that safety, efficacy, and traceability be carefully considered; long-term post marketing studies should be implemented to allow physicians to gain confidence in Biosimilars.

  • Track 15-1Biotechnologic drug
  • Track 15-2Monoclonal antibody
  • Track 15-3Fusion protein
  • Track 15-4Biologic drug
  • Track 15-5Anti–tumor necrosis factor

Biopharmaceutical are also called medical product these Biopharmaceuticals includes blood, blood components, gene therapy, Recombinant therapeutic protein. Biopharmaceutical informatics is used in information technology, molecular modeling and biologic drug development. Development of databases containing the experimental data on biophysical stability, safety along with molecular sequence

  • Track 16-1Applications of computation in Biologic drug development
  • Track 16-2Protein sequence-structural contexts and degradation reaction mechanisms
  • Track 16-3Creation of databases and data mining
  • Track 16-4Pre-clinical immunogenicity risk assessment of Biotherapeutics
  • Track 16-5Monoclonal antibodies (Various)
  • Track 16-6Blood components
  • Track 16-7Vaccines
  • Track 16-8Biopharmaceutical Research

The objective of this track is to suggest the Biowaivers potential of Biopharmaceutical classification system which is known to increase the solubility, dissolution, oral absorption of water insoluble drugs. Biopharmaceutics Classification System and Invitro and Invivo classification discusses about ADME pathways of different drugs. This track also includes BCS biowaivers, in vitro diffusion cells for dissolution testing in formulation development, in vitro preclinical ADME/BCS testing. Until in vitro in vivo correlation achieves the required degree, the Biosimilar drug will not be able to meet the needs of the original drug candidate. Hence the proportion of BCS and IVIVC based biowaivers are fairly low ~0.5-1% of total pharmaceutical products.

  • Track 17-1BCS biowaivers
  • Track 17-2Preclinical and clinical testing for oral drug delivery
  • Track 17-3Waiver for In vivo Bioavailability or Bioequivalence
  • Track 17-4Consideration of Biowaiver extensions for BCS class III drugs
  • Track 17-5In vitro diffusion cells for dissolution testing in formulation development
  • Track 17-6Dissolution testing in drug formulation
  • Track 17-7In vitro preclinical ADME/BCS testing
  • Track 17-8In vitro drug product research

Biosimilar guidelines for Pharmacovigilance practice and Pharmacoepidemiology are the points that shall be laid emphasis in this session. U.S. average annual spending growth from 2002 to 2007 was 16% for Biologics, compared with 3.7% for drugs. In same proportion Pharmacovigilance for Biosimilars has been comparatively more than other pharmaceutical products. Biosimilars are interlinked with FDA activities that have as of now been declared to incorporate upgraded following and follow-up of post market issues, arranged changes in AERS, and pilots of new post advertise medicate observing systems. Current difficulties in Pharmacovigilance, adverse medication responses with pharmaceutical items, Biosimilar rules for Pharmacovigilance practice and pharmacoepidemiology are the focuses that should be laid accentuation in this session.

  • Track 18-1Current problems in Pharmacovigilance
  • Track 18-2Adverse drug reactions with Pharmaceutical products
  • Track 18-3Detection and evaluation of drug safety signals
  • Track 18-4Improve Pharmacovigilance through Patient and Provider Education
  • Track 18-5Regulatory updates and key drivers for registration approvals in US, EU and China
  • Track 18-6Regulatory requirement for Biosimilar IND filing in the US
  • Track 18-7Role of Pharma industries in the improvement of Pharmacovigilance system

The "Generic Drugs Market: 2015 - 2030 - Opportunities, Challenges, Strategies & Forecasts" report presents an in-depth assessment of the generic drugs and Analysis of key therapeutic areas and leading generic drugs  pufecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, Pharmaceutical Industry  opportunities, future road map, Following key trends, market drivers, challenges, Analysis of key therapeutic areas and leading generic trends ,value chain, ecosystem player profiles and strategies and  Regulatory landscape of global trends  throughout the globe The report also presents market size forecasts for generic drugs from 2017 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries.

  • Track 19-1Clinical development strategies for Biosimilars
  • Track 19-2Advances in Biosimilar Production & Technologies
  • Track 19-3Scale Up of Biosimilars
  • Track 19-4Business Development in biosimilar
  • Track 19-5Major market trends & Featured regional market trends

For this rapidly growing industry sector, little consensus or authoritative information is available yet regarding how and where biosimilar products will be produced. The future of their manufacturing is still up in the air. Much discussion among experts has focused on a dramatic up-tick in Contract Manufacturing Organizations (CMOs) involvement with process development projects and clinical-scale manufacturing for Biosimilars. None have really set up commercial-scale projects (yet), however. Many such companies are publicly discussing large-scale partnerships for production in India and elsewhere in Asia. On the other hand, some Biosimilars sponsors are establishing relationships with smaller biotech CMOs that have demonstrated expertise in efficiency or lower-cost business models

  • Track 20-1Multiproduct or dedicated single product plants
  • Track 20-2Major markets or developing countries
  • Track 20-3Single-use, stainless steel or hybrid
  • Track 20-4Continuous bioprocessing

Pharmacology is the branch of solution and science worried with the investigation of medication action where a medication can be comprehensively characterized as any man-made, characteristic, or endogenous (from inside body) particle which applies a biochemical and additionally physiological impact on the cell, tissue, organ, or living being (once in a while the word Pharmacon is utilized as a term to envelop these endogenous and exogenous bioactive species). Sedate improvement is the way toward conveying another pharmaceutical medication to the market once a lead compound has been distinguished through the procedure of medication revelation. It incorporates pre-clinical research on microorganisms and creatures, petitioning for administrative status, for example, by means of the United States Food and Drug Administration for an investigational new generic medication to start clinical trials on people, and may incorporate the progression of acquiring administrative endorsement with another medication application to showcase the medications and Increase Global Pharma Market

  • Track 21-1Clinical pharmacology and Drug addictions
  • Track 21-2Characterization of biologically active compounds
  • Track 21-3Recent advancements in research and developments
  • Track 21-4Recent advances in computer aided drug design
  • Track 21-5Novel Approaches in drug discovery

Globalization of Biosimilars is about the generic drugs impact on Global Biosimilar market, Cost and risk management, adopting innovative mechanisms such as risk-sharing arrangement, European market for Biosimilars. A growing global market for Biosimilars is gaining momentum in response to the expiration of patents for a number of key Biologics and consumer demand to reduce treatment costs. Thus, according to Research and Markets, the global biosimilar market, valued at $2 billion in 2012 is projected to reach $19.4 billion by 2018.

  • Track 22-1Global impact of Biosimilars over generics
  • Track 22-2Economic aspect towards Biosimilars
  • Track 22-3Biosimilars in global market
  • Track 22-4Investment and returns on Biosimilars
  • Track 22-5Cost and risk management
  • Track 22-6Adopting innovative mechanisms such as risk-sharing arrangement
  • Track 22-7European market for Biosimilars
  • Track 22-8Global P&R models for the Biosimilars and generics market

Biotherapeutics more often than not alludes to helpful materials created utilizing organic means, including recombinant DNA innovation. Biotherapeutics are fundamentally operators, used to treat and maintain a strategic distance from human malady by interrelating with the microbial environment of the host. Biotherapeutics can target particular particles inside the human body, and have a decent reputation with patient wellbeing. Fabricating biotherapeutics is mind boggling, as they are bigger mixes in both size and structure, and can be touchy to ecological conditions.

  • Track 23-1Advancements in Biotherapeutics
  • Track 23-2Biotech and Biosimilar Products
  • Track 23-3Antibody based therapeutics
  • Track 23-4Therapeutic Antibodies and Fc Fusion Proteins

Biosimilar products are also produced from plants. Plants are the richest store house of diverse class of phytochemicals. Production of Biosimilar products in tobacco plants is on the verge of completion of the first step in their research. These also includes Transgenic plants, Post translational genetics, Fermentation culture, Molecular farming. For biosimilar manufacturers this session has the potential to bring up new avenues in their product range. Pharmacognosy researchers would find this track highly interesting and informative towards their research work. Proportion of plant produced Biosimilars are comparably low. However, an increased level of plant sourced Biologics ~25% is owned to be seen in the market. Especially Biologics derived from the plant sources are expected to occupy about more than 20% of all Biologics.

  • Track 24-1Transgenic plants
  • Track 24-2Post translational genetics
  • Track 24-3Fermentation culture
  • Track 24-4Molecular farming